Investors & Media

Webcast ImageWebcast
Ionis R&D Day (Live)
07/13/16 at 8:00 a.m. ET
Ionis R&D Day
Wednesday, July 13, 2016 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
06/22/16Ionis Pharmaceuticals to Host R&D Day
- Webcast on Wednesday, July 13 at 8:30 a.m. ET at CARLSBAD, Calif., June 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will host an R&D Day on Wednesday, July 13 at 8:00 a.m. Eastern Time at The London NYC in New York, NY. The agenda for the meeting is as follows: 8:00 a.m. – 8:30 a.m. ET – Breakfast 8:30 a.m. – 12:30 p.m. ET – Presentations 12:30 p.m. – 1:00 p.m. ET – Networking luncheon In addi... 
Printer Friendly Version
05/26/16Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
Conference call scheduled for 9 am Eastern Time today CARLSBAD, Calif., May 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on the IONIS-TTRRx program.  Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy.  Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardi... 
Printer Friendly Version
05/23/16Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
CARLSBAD, Calif. and HOUSTON, May 23, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and The University of Texas MD Anderson Cancer Center today announced the formation of a strategic alliance to discover and develop novel cancer therapeutics. Combining advances made with Ionis' antisense technology, which provides enhanced potency for effectively engaging targets in solid and liquid tumors, with MD Anderson's expertise will allow Ionis and MD Anderson to develop novel therapeut... 
Printer Friendly Version
05/16/16Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
Study designed to support regulatory filings in U.S., E.U. and Canada for volanesorsen CAMBRIDGE, Mass., May 16, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing innovative treatments for serious cardiometabolic diseases, today announced the completion of enrollment in the COMPASS study, a randomized, double-blind, placebo-controlled, Phase 3 study of volanesorsen in patients with severe hypertriglyce... 
Printer Friendly Version
Upcoming EventsMore >>
07/13/16 8:00 a.m. ET
Ionis R&D Day

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.